Paratek Pharmaceuticals completed the merger with Optinose in a $330m deal.

Paratek Pharmaceuticals, a commercial-stage biopharmaceutical company, completed the merger with Optinose, a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose, and throat and allergy specialists, in a $330m deal. “Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty therapeutics company, focused on addressing significant unmet medical needs. Our medical and commercial teams are deeply experienced with capabilities focused on bringing innovative treatments to specialists and primary care providers that address the needs of their patients. This transaction establishes a strong platform for us to continue to leverage these capabilities as we move forward to explore opportunities to expand our portfolio through future product acquisitions," Evan Loh, MD, Paratek Chief Executive Officer.